ClinicalTrialsFinder
RecruitingNot ApplicableNCT06515262

Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM

A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy

Sponsor

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

Enrollment

10 participants

Start Date

Jul 1, 2024

Study Type

INTERVENTIONAL

Conditions

Relapsed/Refractory Multiple Myeloma

Summary

This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of bispecific BCMA-GPRC5D CAR-T cells in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria18

  • The patient or his/her guardian understands and voluntarily signs the informed consent, and is expected to complete the follow-up examination and treatment of the study procedure;
  • Age 18-75 years old, gender unlimited;
  • Diagnosed as Multiple Myeloma (MM) according to the international standard for multiple myeloma (IMWG);
  • The presence of measurable disease at screening meets one of the following criteria:Serum M-protein ≥ 1.0 g/dL or Urine M-protein ≥ 200 mg/24h or diagnosed as Light-chain MM without measurable disease in serum and urine; Serum free light chain ≥ 10 mg/dL with an abnormal κ/λ ratio;
  • Patients must relapse or be refractory after three or more lines of therapy, which at least include: one Proteasome Inhibitor (PI), one Immunomodulatory Drug (IMiD), and one anti-CD38 monoclonal antibody;
  • diagnosed as relapsed/refractory disease or primary refractory disease;
  • The last treatment is ineffective, or the disease progresses within 60 days after the end of the last therapy;
  • The patient has recovered from the toxicity of the prior treatment, i.e., CTCAE toxicity grade \< 2 (unless the abnormality is related to the tumor or is stable as judged by the investigator and has little impact on safety or efficacy);
  • ECOG score 1-2 points and the expected survival period ≥ 3 months;
  • Liver, kidney and cardiopulmonary functions meet the following requirements:
  • Total bilirubin ≤ 1.5×ULN, alanine aminotransferase (ALT) ≤ 3 × ULN and aspartate aminotransferase (AST) ≤ 3 × ULN;
  • Serum creatinine ≤ 1.5×ULN, or creatinine clearance ≥ 60 mL/min;
  • Hemoglobin (Hb) ≥ 50 g/L without prior blood transfusion within 7 days;
  • Baseline peripheral oxygen saturation \> 92%;
  • Corrected serum calcium ≤ 12.5 mg/dL (≤ 3.1 mmol/L) or free (ionized, ionic) calcium ≤ 6.5 mg/dL (≤ 1.6 mmol/L);
  • Left ventricular ejection fraction (LVEF) \> 45%, without confirmed pericardiac effusion and abnormal electrocardiography with clinical significance;
  • Without clinically significant pleural effusion;
  • Venous access could be established; without contraindications of apheresis.

Exclusion Criteria20

  • Have been diagnosed with or treated for aggressive malignancies other than multiple myeloma;
  • Prior antitumor therapy (prior to blood collection for CAR-T preparation) : targeted therapy, epigenetic therapy, or investigational drug therapy within 14 days or at least 5 half-lives, whichever is shorter;
  • It is suspected that MM has involved the central nervous system or meninges and has been confirmed by MRI or CT, or there are other active central nervous system diseases;
  • Patients with Fahrenheit macroglobulinemia, POEMS syndrome, or primary AL, amyloidosis;
  • Subjects with positive HBsAg or HBcAb positive and peripheral blood HBV DNA titer is higher than the lower limit of detection of the research institution; HCV antibody positive; HIV antibody positive; CMV DNA titer is higher than the lower limit of detection of the research institution; EBV DNA titer is higher than the lower limit of detection of the research institution;
  • Patients have a severe allergic history;
  • Any unstable systemic disease: including but not limited to unstable angina, cerebrovascular accident or transient cerebral ischemia (within 6 months before screening), myocardial infarction (within 6 months before screening), congestive heart failure \[New York Heart Association (NYHA) classification ≥ grade III\];
  • Systemic diseases judged by researchers to be unstable: including but not limited to severe liver, kidney or metabolic diseases requiring drug treatment;
  • Patients with acute/chronic graft-versus-host disease (GVHD) or requiring immunosuppressive therapy for GVHD within 6 months prior to screening;
  • Active autoimmune or inflammatory diseases of the nervous system;
  • Patients develop oncology emergencies and need to be treated before screening or infusion;
  • Uncontrolled infections that need antibiotics treatment;
  • Exposure to hematopoietic growth factor of cells within 1-2 weeks before apheresis;
  • Exposure to Corticosteriods or immunosuppressive agents within 2 weeks before apheresis;
  • Patients receive a major surgical operation within 4 weeks before lymphodepletion or do not recover completely before the enrollment; or plan to receive a major surgical operation during the study period;
  • Live attenuated vaccine within 4 weeks before screening;
  • Persons with serious mental illness;
  • Alcoholics or persons with a history of drug abuse;
  • Pregnant or Lactating Women; Patients and his or her spouse have a fertility plan within two years after CAR-T cell infusion;
  • Any unsuitable to participate in this trial judged by the investigator.

Interventions

BIOLOGICALAnti-BCMA-GPRC5D CAR-T cells infusion

Subiects who meet the enrollment conditions will receive intravenous infusion of anti-BCMA-GPRC5D CAR-T Cells after lymphodepleting therapy.

Locations(1)

Sanbin Wang

Kunming, Kunming, Yunnan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06515262

Related Trials

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

NCT0497360583 locations

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT0516058486 locations

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

NCT0586201211 locations

ELISA in Relapsed/Refractory MM

NCT068328653 locations

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

NCT07391657108 locations